Teva Pharmaceutical (NASDAQ: TEVA) reported Q4 EPS of $1.59, $0.01 better than the analyst estimate of $1.58. Revenue for the quarter came in at $5.68 billion versus the consensus estimate of $5.61 billion.

For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.

Earnings